<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131759">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386684</url>
  </required_header>
  <id_info>
    <org_study_id>P12-811</org_study_id>
    <nct_id>NCT01386684</nct_id>
  </id_info>
  <brief_title>Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study</brief_title>
  <official_title>Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMX Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Canadian Real Life Evaluation of the
      Effectiveness of Lupron in the Management of Prostate Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design.
      Patients with Prostate Cancer who are prescribed Lupron will be entered into the study
      cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6,
      12, 18, 24, 30 and 36 months after baseline. Treatment of the patients and follow up will be
      according to the physician's judgment, regional regulations and the product monograph.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of progression-free survival, defined as the time from patient recruitment to biochemical progression based on doubling of PSA (Prostate Specific Antigen) velocity or PSA &gt; 5.0, objective tumor progression</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of refractory disease.</measure>
    <time_frame>at every visit for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of total serum testosterone.</measure>
    <time_frame>at every visit for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum PSA (Prostatic Specific Antigen)</measure>
    <time_frame>at every visit for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life</measure>
    <time_frame>at every visit for 36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">553</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer subjects</arm_group_label>
    <description>Prostate Cancer subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be enrolled from the offices of university or community
        urologists/oncologists across Canada treating patients with PCa.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Has provided written informed consent allowing the use of their data for the study and
        providing permission for contact by the study personnel

        ii. Diagnosed with Prostate Cancer

        iii. Prescribed Lupron as part of his treatment by his treating physician

        Exclusion Criteria:

        i. Currently participating in another prospective study including controlled clinical
        trials and observational studies.

        â€¢ Exclusion of patient participating in other observational studies is necessary in order
        to prevent over-representation of specific patients in different studies, practical
        considerations regarding authority to utilize the patient's data and statistical issues
        related to lack of independence of the observations in different studies triggering
        multiplicity issues

        ii. Patient cannot or will not sign informed consent

        iii. Survival expectancy less than 2-3 years as per the treating physician's judgment

        iv. Presence of other condition that, in the opinion of the treating physician, prohibits
        the patient from participating in the study or obscures the assessment of the treatment of
        Prostate Cancer

        v. History of alcohol or drug abuse

        vi. No longer than 6 months of therapy if currently on luteinizing hormone-releasing
        hormone (LHRH) treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56448</name>
      <address>
        <city>Abbottsford</city>
        <zip>V2S 3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56450</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54902</name>
      <address>
        <city>Brampton</city>
        <zip>L6T 4S5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54543</name>
      <address>
        <city>Brantford</city>
        <zip>N8S 6T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54904</name>
      <address>
        <city>Burlington</city>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57123</name>
      <address>
        <city>Burlington</city>
        <zip>L7S 1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57032</name>
      <address>
        <city>Chicoutimi</city>
        <zip>G7H 4J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55512</name>
      <address>
        <city>Granby</city>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56447</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56452</name>
      <address>
        <city>Guelph</city>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89053</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1Y4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56446</name>
      <address>
        <city>Kelowna</city>
        <zip>V1W 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54903</name>
      <address>
        <city>Laval</city>
        <zip>H7G 2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54907</name>
      <address>
        <city>London</city>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75313</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 74493</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54909</name>
      <address>
        <city>Newmarket</city>
        <zip>L3X 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54908</name>
      <address>
        <city>North York</city>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54542</name>
      <address>
        <city>Oakville</city>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 79774</name>
      <address>
        <city>Oshawa</city>
        <zip>L19 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 61303</name>
      <address>
        <city>Oshawa</city>
        <zip>L1G 8A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56449</name>
      <address>
        <city>Owensound</city>
        <zip>N4K 2J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56917</name>
      <address>
        <city>Peterborough</city>
        <zip>K9H 1T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 61722</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 7B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56445</name>
      <address>
        <city>Pointe-Claire</city>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 64145</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 3X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54906</name>
      <address>
        <city>Scarborough</city>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54905</name>
      <address>
        <city>Scarborough</city>
        <zip>M1S 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89633</name>
      <address>
        <city>St. John</city>
        <zip>E2L 3J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56443</name>
      <address>
        <city>Surrey,</city>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57762</name>
      <address>
        <city>Toronto</city>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 60843</name>
      <address>
        <city>Toronto</city>
        <zip>M4C 5M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56444</name>
      <address>
        <city>Toronto</city>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56451</name>
      <address>
        <city>Toronto</city>
        <zip>M6S 4W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56453</name>
      <address>
        <city>Trois-Rivieres</city>
        <zip>G9A 3V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55513</name>
      <address>
        <city>Val d'Or</city>
        <zip>J9P 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 22, 2016</lastchanged_date>
  <firstreceived_date>June 30, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
